Peanut Allergy is a common and potentially life-threatening food allergy caused by an immune system overreaction to peanut proteins. Even small amounts can trigger symptoms ranging from mild (hives, itching) to severe (anaphylaxis).
<h2 dir="ltr">Epidemiology Segmentation</h2>
<ul>
<li dir="ltr" aria-level="1">
Total Diagnosed Prevalent Cases of Peanut Allergy
</li>
<li dir="ltr" aria-level="1">
Gender-Specific Cases of Peanut Allergy
</li>
<li dir="ltr" aria-level="1">
Age-Specific Cases of Peanut Allergy
</li>
<li dir="ltr" aria-level="1">
Severity-Specific Cases of Peanut Allergy
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/peanut-allergy-epidemiology-forecast">Peanut Allergy Epidemiology</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the U.S. had the highest peanut allergy prevalence in the 7MM, with ~5.1 million diagnosed cases.
</li>
<li dir="ltr" aria-level="1">
Germany led the EU4+UK with ~1.1 million prevalent cases.
</li>
<li dir="ltr" aria-level="1">
In Japan, most cases were reported in the 41&ndash;64 age group, followed by those aged 65+.
</li>
<li dir="ltr" aria-level="1">
Mild to moderate cases were more common than severe cases.
</li>
<li dir="ltr" aria-level="1">
Peanut allergy was more prevalent in females than males.
</li>
</ul>
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/peanut-allergy-market">Peanut Allergy Market</a></h3>
<ul>
<li dir="ltr" aria-level="1">
In 2024, the U.S. led the peanut allergy treatment market with ~USD 340 million in revenue.
</li>
<li dir="ltr" aria-level="1">
Germany had the highest market size in the EU4+UK, while Spain had the lowest.
</li>
<li dir="ltr" aria-level="1">
The pipeline includes BTK inhibitors, immunostimulants, immunomodulators, immunosuppressants, and IL-13 receptor-targeting therapies.
</li>
<li dir="ltr" aria-level="1">
By 2034, Viaskin (Age 4&ndash;7) is expected to generate the highest revenue among emerging therapies in the U.S.
</li>
</ul>
<h3 dir="ltr">Peanut Allergy Market Drivers</h3>
<ul>
<li dir="ltr" aria-level="1">
The increasing incidence of peanut allergies, especially among children, is driving demand for preventive and therapeutic solutions.
</li>
<li dir="ltr" aria-level="1">
Emerging treatments like oral immunotherapy (e.g., Palforzia) are expanding options beyond avoidance, fueling market growth.
</li>
</ul>
<h3 dir="ltr">Peanut Allergy Market Barriers</h3>
<ul>
<li dir="ltr" aria-level="1">
New therapies can be expensive, limiting accessibility and adoption among broader patient populations.
</li>
<li dir="ltr" aria-level="1">
Risk of severe allergic reactions during desensitization treatments may deter patients and caregivers from opting for immunotherapy.
</li>
</ul>
<h3 dir="ltr">Peanut Allergy Key Therapies</h3>
<ul>
<li dir="ltr" aria-level="1">
Viaskin (DBV712) peanut patch
</li>
<li dir="ltr" aria-level="1">
Remibrutinib (LOU064)
</li>
<li dir="ltr" aria-level="1">
PVX108 (AVX-201)
</li>
<li dir="ltr" aria-level="1">
Sublingual Immunotherapy (SLIT)-Tablet
</li>
</ul>
And others.&nbsp;
<h3 dir="ltr"><a href="https://www.delveinsight.com/report-store/peanut-allergy-pipeline-insight">Peanut Allergy Key Players</a></h3>
<ul>
<li dir="ltr" aria-level="1">
Stallergenes Greer
</li>
<li dir="ltr" aria-level="1">
Roche
</li>
<li dir="ltr" aria-level="1">
Novartis
</li>
<li dir="ltr" aria-level="1">
DBV Technologies
</li>
<li dir="ltr" aria-level="1">
Novartis
</li>
<li dir="ltr" aria-level="1">
Aravax
</li>
<li dir="ltr" aria-level="1">
ALK-Abello
</li>
<li dir="ltr" aria-level="1">
InnoUp Farma
</li>
<li dir="ltr" aria-level="1">
Allergy Therapeutics
</li>
<li dir="ltr" aria-level="1">
Intrommune Therapeutics
</li>
</ul>
And others.

Peanut Allergy Market

Peanut Allergy Market Infographic

Peanut Allergy Market 

Peanut Allergy Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape